Sugi Predict

Sugi Predict / Compounds / SCHEMBL31040915

SCHEMBL31040915

SCHEMBL31040915

CC1(C)OCC(=O)c2ccc(C(F)(F)F)cc21

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TDP2 O95551 2/20 0.43
▸ PARP1 P09874 1/20 0.37
▸ PARP10 Q53GL7 1/20 0.37
▸ PGR P06401 8/20 0.35
▸ LMNA P02545 1/20 0.35
▸ PIM1 P11309 1/20 0.35
▸ PIM3 Q86V86 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ NOTUM Q6P988 1/20 0.33
▸ MAOA P21397 2/20 0.33
▸ MAOB P27338 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ RXFP1 Q9HBX9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31040917 1.00 TDP2 (0.43) TDP2PARP1PARP10PGRLMNA
SCHEMBL31618296 0.82 TDP2 (0.37) TDP2PARP1PARP10PGRLMNA
SCHEMBL31064284 0.82 TDP2 (0.43) TDP2PARP1PARP10PIM1PIM3
SCHEMBL31618347 0.79 TDP2 (0.35) TDP2PARP1PARP10LMNA
SCHEMBL17808127 0.76 TDP2 (0.39) TDP2PGRLMNAALDH1A1MAOB
SCHEMBL31040700 0.76 TDP2 (0.39) TDP2PGRLMNAALDH1A1MAOB
SCHEMBL18440084 0.72 PGR (0.43) PGRNOTUMMAOAMAOB
SCHEMBL31136618 0.70 TDP2 (0.46) TDP2PARP1PARP10PIM1PIM3
SCHEMBL2930402 0.69 MAPT (0.47) TDP2PARP1PARP10ALDH1A1MAOA
SCHEMBL31026824 0.68 PARP1 (0.47) TDP2PARP1PARP10PIM1PIM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122070134-A Use of PRMT5 inhibitors in the treatment of tumors or cancers 上海湃隆生物科技有限公司 2026-05-19 — — CN disclosed
US-20260125380-A1 PRMT5 INHIBITORS AND METHODS OF USE SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) 2026-05-07 — — US disclosed
EP-4592289-A1 NOVEL PRMT5 INHIBITOR AND USE THEREOF Shanghai Apeiron Therapeutics Company Limited (CN) 2025-07-30 — — EP disclosed
WO-2025119326-A1 NOVEL PRMT5 INHIBITOR AND USE THEREOF 上海湃隆生物科技有限公司 2025-06-12 — — WO disclosed
US-20250051331-A1 PRMT5 INHIBITORS AND METHODS OF USE SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) 2025-02-13 — — US disclosed
US-12173002-B2 PRMT5 inhibitors and methods of use SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) 2024-12-24 — — US disclosed
US-20240294528-A1 PRMT5 INHIBITORS AND METHODS OF USE SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) 2024-09-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12173002-B2 PRMT5 inhibitors and methods of use PRMT5, PRMT1, PRMT7 TDP2 975/4885PARP1 1016/4885PARP10 204/4885
US-20250051331-A1 PRMT5 INHIBITORS AND METHODS OF USE PRMT5, PRMT1, PRMT7 TDP2 1568/4885PARP1 925/4885PARP10 210/4885
US-20260125380-A1 PRMT5 INHIBITORS AND METHODS OF USE PRMT1, PRMT5, PRMT6 TDP2 2047/4885PARP1 1252/4885PARP10 403/4885
US-20240294528-A1 PRMT5 INHIBITORS AND METHODS OF USE PRMT5, PRMT1, PRMT3 TDP2 772/4885PARP1 496/4885PARP10 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.